Se busca **candidato/a post-doctoral** para la solicitud de las ayudas destinadas a la atracción de talento convocadas por la Comunidad de Madrid:

Ayudas destinadas a la **atracción de talento investigador** para su incorporación a grupos de investigación de la Comunidad de Madrid, en las siguientes modalidades:

- Modalidad 1: Ayudas para la contratación de doctores con experiencia. **Más información.**

- Modalidad 2: Ayudas para la contratación de jóvenes doctores. **Más información.**

Las solicitudes tienen que ser avaladas por los Departamentos y presentadas en el Servicio de Investigación hasta el día 14 de septiembre de 2017, por lo que es necesario que los interesados se pongan en contacto con nosotros antes del **12 de septiembre de 2017.**

Persona de contacto: María Gómez-Ruiz (msgr@med.ucm.es)

Línea de investigación: Posible papel neuroprotector de los cannabinoides en las ataxias espinocerebelosas.

A continuación se presenta un **breve resumen de la línea de investigación**:
At present, the group is interested in the development of cannabinoid-based therapies for neurodegenerative disorders, for which it collaborates with different groups of Medicinal Chemistry or with pharmaceutical companies working in the development of cannabinoid-based medicines (e.g GW Pharmaceuticals, UK; VivaCell Biotechnology-Spain). The group is contributing in these collaborations with the biological characterization of phytocannabinoids and derivatives, as well as of new cannabinoid compounds, in relation with the identification of their pharmacological targets (mainly their activity at CB1/CB2 receptors), possible combinations of compounds and pharmacological synergies, biological activity in in vitro models, and therapeutic effects in in vivo models of different neurodegenerative disorders, including Huntington's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis/frontotemporal dementia, and autosomal-dominant cerebellar ataxias. The group is particularly interested in developing disease-modifying cannabinoid-based therapies for these disorders, but also in the investigation of the role of the signaling system, the so-called endocannabinoid system, which contains the different targets for these therapies, in the pathogenesis of these disorders. These studies have progressed up to the development of clinical trials in some disorders (e.g. Huntington's disease), and they are in the stage of preclinical validation (e.g. Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis) or pending of the identification of targets (e.g. frontotemporal dementia, autosomal-dominant cerebellar ataxias).

María Gómez Ruiz
Departamento Psicobiología
Universidad Complutense de Madrid
msgr@med.ucm.es